Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: Implications for inflammation and obesity

Obesity Reviews

Volumn 17, Issue 4, 2016, Pages 297-312

  Hersoug, L G ^a,b   Moller P ^a   Loft, S ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE   (Denmark)

Author keywords

Gut microbiota; LPS; Obesity; Transcytosis

Indexed keywords

CARRIER PROTEIN; CD36 ANTIGEN; CHYLOMICRON; HOST FACTOR; LIPOPOLYSACCHARIDE; LIPOPROTEIN; SCAVENGER RECEPTOR BI;

ADIPOCYTE; ADIPOSE TISSUE; ARTICLE; CIRCULATION; ENDOCYTOSIS; ENDOTHELIUM; ENDOTOXEMIA; FAT INTAKE; GRAM NEGATIVE BACTERIUM; HUMAN; HYPERTROPHY; INFLAMMATION; INTESTINE FLORA; LIVER METABOLISM; LYMPH; MACROPHAGE; NONHUMAN; OBESITY; PHENOTYPE; PROTEIN BINDING; PROTEIN TRANSPORT; REGULATORY MECHANISM; TRANSCYTOSIS; ANIMAL; DRUG EFFECTS; MICROBIOLOGY;

ADIPOSE TISSUE; ANIMALS; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; OBESITY;

EID: 84959505464     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12370     Document Type: Article

References (175)

1. Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology 2014; 146: 1449-1458.
2. Koren O, Spor A, Felin J et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc Natl Acad Sci U S A 2011; 108: 4592-4598.
3. Delzenne NM, Cani PD. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev Nutr 2011; 31: 15-31.
4. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. Gut Microbes 2012; 3: 279-288.
5. Masters RK, Reither EN, Powers DA, Yang YC, Burger AE, Link BG. The impact of obesity on US mortality levels: the importance of age and cohort factors in population estimates. Am J Public Health 2013; 103: 1895-1901.
6. WHO. Global Database on Body Mass Index. http://:www.who.int/bmi/index.jsp. 2007.
7. Gualillo O. Mediators of inflammation in obesity and its comorbidities. Mediators Inflamm 2010; 2010.
8. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-846.
9. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11: 886-895.
10. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 2013; 1281: 106-122.
11. Rask-Madsen C, Kahn CR. Tissue-specific insulin signaling, metabolic syndrome, and cardiovascular disease. Arterioscler Thromb Vasc Biol 2012; 32: 2052-2059.
12. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-1808.
13. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab 2005; 288: E741-E747.
14. Giordano A, Murano I, Mondini E et al. Obese adipocytes show ultrastructural features of stressed cells and die of pyroptosis. J Lipid Res 2013; 54: 2423-2436.
15. Zhang LJ, Guerrero-Juarez CF, Hata T et al. Innate immunity. Dermal adipocytes protect against invasive Staphylococcus aureus skin infection. Science 2015; 347: 67-71.
16. Peyrin-Biroulet L, Chamaillard M, Gonzalez F et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007; 56: 577-583.
17. Hillenbrand A, Weiss MF, Knippschild UF, Wolf AM FAU - Huber-Lang M, Huber-Lang M. Sepsis-induced adipokine change with regard to insulin resistance. International Journal of Inflammation 2011; 2012, Article ID 972368, doi:10.1155/2012/972368.
18. Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006; 116: 33-35.
19. Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-1772.
20. Harte AL, Varma MC, Tripathi G et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 2012; 35: 375-382.
21. O'Rourke RW, Lumeng CN. Obesity heats up adipose tissue lymphocytes. Gastroenterology 2013; 145: 282-285.
22. Vieira-Potter VJ. Inflammation and macrophage modulation in adipose tissues Cell Microbiol 2014;16: 1484-1492 doi:10.1111/cmi.12336.
23. Winer S, Chan Y, Paltser G et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat Med 2009; 15: 921-929.
24. Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res 2008; 49: 1894-1903.
25. Molofsky AB, Nussbaum JC, Liang HE et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and alternatively activated macrophages. J Exp Med 2013; 210: 535-549.
26. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011; 30: 16-34.
27. Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol 2004; 76: 514-519.
28. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006; 116: 3015-3025.
29. Erridge C, Samani NJ. Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol 2009; 29: 1944-1949.
30. Caspar-Bauguil S, Kolditz CI, Lefort C et al. Fatty acids from fat cell lipolysis do not activate an inflammatory response but are stored as triacylglycerols in adipose tissue macrophages. Diabetologia 2015; 58: 2627-2636.
31. Moraes-Vieira PM, Yore MM, Dwyer PM, Syed I, Aryal P, Kahn BB. RBP4 activates antigen-presenting cells, leading to adipose tissue inflammation and systemic insulin resistance. Cell Metab 2014; 19: 512-526.
32. Balagopal P, Graham TE, Kahn BB, Altomare A, Funanage V, George D. Reduction of elevated serum retinol binding protein in obese children by lifestyle intervention: association with subclinical inflammation. J Clin Endocrinol Metab 2007; 92: 1971-1974.
33. Yao-Borengasser A, Varma V, Bodles AM et al. Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007; 92: 2590-2597.
34. Norseen J, Hosooka T, Hammarstedt A et al. Retinol-binding protein 4 inhibits insulin signaling in adipocytes by inducing proinflammatory cytokines in macrophages through a c-Jun N-terminal kinase- and toll-like receptor 4-dependent and retinol-independent mechanism. Mol Cell Biol 2012; 32: 2010-2019.
35. Xu J, Gordon JI. Honor thy symbionts. Proc Natl Acad Sci U S A 2003; 100: 10452-10459.
36. Devkota S, Wang Y, Musch MW et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature 2012; 487: 104-108.
37. Lam V, Su J, Koprowski S et al. Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 2012; 26: 1727-1735.
38. Vinolo MA, Rodrigues HG, Nachbar RT, Curi R. Regulation of inflammation by short chain fatty acids. Nutrients 2011; 3: 858-876.
39. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci 2013; 70: 631-659.
40. Santos NC, Silva AC, Castanho MA, Martins-Silva J, Saldanha C. Evaluation of lipopolysaccharide aggregation by light scattering spectroscopy. Chembiochem 2003; 4: 96-100.
41. Erridge C, Attina T, Spickett CM, Webb DJ. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am J Clin Nutr 2007; 86: 1286-1292.
42. Laugerette F, Vors C, Geloen A et al. Emulsified lipids increase endotoxemia: possible role in early postprandial low-grade inflammation. J Nutr Biochem 2011; 22: 53-59.
43. Ghoshal S, Witta J, Zhong J, De VW, Eckhardt E. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90-97.
44. Moreira AP, Texeira TF, Ferreira AB, Peluzio MC, Alfenas RC. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia. Br J Nutr 2012; 108: 801-809.
45. Taira R, Yamaguchi S, Shimizu K, Nakamura K, Ayabe T, Taira T. Bacterial cell wall components regulate adipokine secretion from visceral adipocytes. J Clin Biochem Nutr 2015; 56: 149-154.
46. Amar J, Chabo C, Waget A et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011; 3: 559-572.
47. Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 2006; 131: 589-605.
48. Dube PE, Rowland KJ, Brubaker PL. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I. Endocrinology 2008; 149: 291-301.
49. Cani PD, Possemiers S, Van de Wiele T et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091-1103.
50. Medzhitov R, Horng T. Transcriptional control of the inflammatory response. Nat Rev Immunol 2009; 9: 692-703.
51. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195.
52. Triantafilou M, Triantafilou K, Fernandez N. Rough and smooth forms of fluorescein-labelled bacterial endotoxin exhibit CD14/LBP dependent and independent binding that is influenced by endotoxin concentration. Eur J Biochem 2000; 267: 2218-2226.
53. Zanoni I, Ostuni R, Marek LR et al. CD14 controls the LPS-induced endocytosis of Toll-like receptor 4. Cell 2011; 147: 868-880.
54. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23: 443-463.
55. Hofmann AF, Eckmann L. How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci U S A 2006; 103: 4333-4334.
56. Li T, Chiang JY. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014; 66: 948-983.
57. Ziegler TR, Cole CR. Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure. Curr Gastroenterol Rep 2007; 9: 463-467.
58. Kaufman SS, Loseke CA, Lupo JV et al. Influence of bacterial overgrowth and intestinal inflammation on duration of parenteral nutrition in children with short bowel syndrome. J Pediatr 1997; 131: 356-361.
59. Ridlon JM, Kang DJ, Hylemon PB, Bajaj JS. Bile acids and the gut microbiome. Curr Opin Gastroenterol 2014; 30: 332-338.
60. Bjursell M, Wedin M, Admyre T et al. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 2013; 8: e64721.
61. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, van Erpecum KJ. Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 1801; 2010: 683-692.
62. Sanyal AJ. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. Dig Dis 2015; 33: 426-432.
63. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-693.
64. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe 2007; 2: 371-382.
65. Kelly CJ, Colgan SP, Frank DN. Of microbes and meals: the health consequences of dietary endotoxemia. Nutr Clin Pract 2012; 27: 215-225.
66. Estaki M, DeCoffe D, Gibson DL. Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity. World J Gastroenterol 2014; 20: 15650-15656.
67. Kaliannan K, Hamarneh SR, Economopoulos KP et al. Intestinal alkaline phosphatase prevents metabolic syndrome in mice. Proc Natl Acad Sci U S A 2013; 110: 7003-7008.
68. Corthesy B. Roundtrip ticket for secretory IgA: role in mucosal homeostasis? J Immunol 2007; 178: 27-32.
69. Hapfelmeier S, Lawson MA, Slack E et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science 2010; 328: 1705-1709.
70. Moreau MC, Ducluzeau R, Guy-Grand D, Muller MC. Increase in the population of duodenal immunoglobulin A plasmocytes in axenic mice associated with different living or dead bacterial strains of intestinal origin. Infect Immun 1978; 21: 532-539.
71. De SK, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol Lett 2005; 27: 1337-1347.
72. Ouhara K, Komatsuzawa H, Shiba H et al. Actinobacillus actinomycetemcomitans outer membrane protein 100 triggers innate immunity and production of beta-defensin and the 18-kilodalton cationic antimicrobial protein through the fibronectin-integrin pathway in human gingival epithelial cells. Infect Immun 2006; 74: 5211-5220.
73. Yu FS, Cornicelli MD, Kovach MA et al. Flagellin stimulates protective lung mucosal immunity: role of cathelicidin-related antimicrobial peptide. J Immunol 2010; 185: 1142-1149.
74. Elsbach P. The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense. J Leukoc Biol 1998; 64: 14-18.
75. Elsbach P, Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 1998; 10: 45-49.
76. Levy O, Sisson RB, Kenyon J, Eichenwald E, Macone AB, Goldmann D. Enhancement of neonatal innate defense: effects of adding an N-terminal recombinant fragment of bactericidal/permeability-increasing protein on growth and tumor necrosis factor-inducing activity of gram-negative bacteria tested in neonatal cord blood ex vivo. Infect Immun 2000; 68: 5120-5125.
77. Ulevitch RJ, Tobias PS. Recognition of gram-negative bacteria and endotoxin by the innate immune system. Curr Opin Immunol 1999; 11: 19-22.
78. Levy O, Ooi CE, Elsbach P, Doerfler ME, Lehrer RI, Weiss J. Antibacterial proteins of granulocytes differ in interaction with endotoxin. Comparison of bactericidal/permeability-increasing protein, p15s, and defensins. J Immunol 1995; 154: 5403-5410.
79. Gazzano-Santoro H, Meszaros K, Birr C et al. Competition between rBPI23, a recombinant fragment of bactericidal/permeability-increasing protein, and lipopolysaccharide (LPS)-binding protein for binding to LPS and gram-negative bacteria. Infect Immun 1994; 62: 1185-1191.
80. Schwartz GJ. Gut fat sensing in the negative feedback control of energy balance-recent advances. Physiol Behav 2011; 104: 621-623.
81. Newberry EP, Davidson NO. Intestinal lipid absorption, GLP-2, and CD36: still more mysteries to moving fat. Gastroenterology 2009; 137: 775-778.
82. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009; 296: E1183-E1194.
83. Wang TY, Liu M, Portincasa P, Wang DQ. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Invest 2013; 43: 1203-1223.
84. Abumrad NA, Davidson NO. Role of the gut in lipid homeostasis. Physiol Rev 2012; 92: 1061-1085.
85. Siddiqi S, Saleem U, Abumrad NA et al. A novel multiprotein complex is required to generate the prechylomicron transport vesicle from intestinal ER. J Lipid Res 2010; 51: 1918-1928.
86. Mansbach CM, Siddiqi SA. The biogenesis of chylomicrons. Annu Rev Physiol 2010; 72: 315-333.
87. Mansbach CM, Gorelick F. Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons. Am J Physiol Gastrointest Liver Physiol 2007; 293: G645-G650.
88. Buttet M, Traynard V, Tran TT, Besnard P, Poirier H, Niot I. From fatty-acid sensing to chylomicron synthesis: role of intestinal lipid-binding proteins. Biochimie 2014; 96: 37-47.
89. Tran TT, Poirier H, Clement L et al. Luminal lipid regulates CD36 levels and downstream signaling to stimulate chylomicron synthesis. J Biol Chem 2011; 286: 25201-25210.
90. Neculai D, Schwake M, Ravichandran M et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36. Nature 2013; 504: 172-176.
91. Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 1997; 272: 17551-17557.
92. Connelly MA, Klein SM, Azhar S, Abumrad NA, Williams DL. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake. J Biol Chem 1999; 274: 41-47.
93. Gu X, Trigatti B, Xu S, Acton S, Babitt J, Krieger M. The efficient cellular uptake of high density lipoprotein lipids via scavenger receptor class B type I requires not only receptor-mediated surface binding but also receptor-specific lipid transfer mediated by its extracellular domain. J Biol Chem 1998; 273: 26338-26348.
94. Brundert M, Heeren J, Merkel M et al. Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res 2011; 52: 745-758.
95. Vishnyakova TG, Bocharov AV, Baranova IN et al. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 2003; 278: 22771-22780.
96. Abreu MT, Arnold ET, Thomas LS et al. TLR4 and MD-2 expression is regulated by immune-mediated signals in human intestinal epithelial cells. J Biol Chem 2002; 277: 20431-20437.
97. Neal MD, Leaphart C, Levy R et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176: 3070-3079.
98. Lotz M, Gutle D, Walther S, Menard S, Bogdan C, Hornef MW. Postnatal acquisition of endotoxin tolerance in intestinal epithelial cells. J Exp Med 2006; 203: 973-984.
99. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med 2002; 195: 559-570.
100. Beaslas O, Cueille C, Delers F et al. Sensing of dietary lipids by enterocytes: a new role for SR-BI/CLA-1. PLoS One 2009; 4: e4278.
101. Karpe F, Olivecrona T, Hamsten A, Hultin M. Chylomicron/chylomicron remnant turnover in humans: evidence for margination of chylomicrons and poor conversion of larger to smaller chylomicron remnants. J Lipid Res 1997; 38: 949-961.
102. Cartwright IJ, Higgins JA. Increased dietary triacylglycerol markedly enhances the ability of isolated rabbit enterocytes to secrete chylomicrons: an effect related to dietary fatty acid composition. J Lipid Res 1999; 40: 1858-1866.
103. Chaudhry KK, Samak G, Shukla PK et al. ALDH2 deficiency promotes ethanol-induced gut barrier dysfunction and fatty liver in mice. Alcohol Clin Exp Res 2015; 39: 1465-1475.
104. Vreugdenhil AC, Rousseau CH, Hartung T, Greve JW, Van V, Buurman WA. Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons. J Immunol 2003; 170: 1399-1405.
105. Lobo MV, Huerta L, Ruiz-Velasco N et al. Localization of the lipid receptors CD36 and CLA-1/SR-BI in the human gastrointestinal tract: towards the identification of receptors mediating the intestinal absorption of dietary lipids. J Histochem Cytochem 2001; 49: 1253-1260.
106. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab 2009; 297: E271-E288.
107. Cryer A, Riley SE, Williams ER, Robinson DS. Effect of nutritional status on rat adipose tissue, muscle and post-heparin plasma clearing factor lipase activities: their relationship to triglyceride fatty acid uptake by fat-cells and to plasma insulin concentrations. Clin Sci Mol Med 1976; 50: 213-221.
108. Hultin M, Savonen R, Olivecrona T. Chylomicron metabolism in rats: lipolysis, recirculation of triglyceride-derived fatty acids in plasma FFA, and fate of core lipids as analyzed by compartmental modelling. J Lipid Res 1996; 37: 1022-1036.
109. Ross AC, Pasatiempo AM, Green MH. Chylomicron margination, lipolysis, and vitamin a uptake in the lactating rat mammary gland: implications for milk retinoid content. Exp Biol Med (Maywood) 2004; 229: 46-55.
110. Braun JE, Severson DL. Regulation of the synthesis, processing and translocation of lipoprotein lipase. Biochem J 1992; 287: 337-347.
111. Karpe F, Bickerton AS, Hodson L, Fielding BA, Tan GD, Frayn KN. Removal of triacylglycerols from chylomicrons and VLDL by capillary beds: the basis of lipoprotein remnant formation. Biochem Soc Trans 2007; 35: 472-476.
112. Hultin M, Carneheim C, Rosenqvist K, Olivecrona T. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 1995; 36: 2174-2184.
113. Fraser R, Dobbs BR, Rogers GW. Lipoproteins and the liver sieve: the role of the fenestrated sinusoidal endothelium in lipoprotein metabolism, atherosclerosis, and cirrhosis. Hepatology 1995; 21: 863-874.
114. Bjorkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and lipid composition between human chylomicron remnants and very low density lipoproteins isolated from fasting and postprandial plasma. J Lipid Res 1998; 39: 1412-1420.
115. Breckenridge WC, Little JA, Steiner G, Chow A, Poapst M. Hypertriglyceridemia associated with deficiency of apolipoprotein C-II. N Engl J Med 1978; 298: 1265-1273.
116. Kinnunen PK, Jackson RL, Smith LC, Gotto AM Jr, Sparrow JT. Activation of lipoprotein lipase by native and synthetic fragments of human plasma apolipoprotein C-II. Proc Natl Acad Sci U S A 1977; 74: 4848-4851.
117. Backhed F, Ding H, Wang T et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A 2004; 101: 15718-15723.
118. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A 2007; 104: 979-984.
119. Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005; 102: 11070-11075.
120. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031.
121. Brun P, Castagliuolo I, Di LV et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G518-G525.
122. Ji Y, Sakata Y, Tso P. Nutrient-induced inflammation in the intestine. Curr Opin Clin Nutr Metab Care 2011; 14: 315-321.
123. Mathurin P, Deng QG, Keshavarzian A, Choudhary S, Holmes EW, Tsukamoto H. Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology 2000; 32: 1008-1017.
124. Bala S, Marcos M, Gattu A, Catalano D, Szabo G. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One 2014; 9: e96864.
125. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000; 32: 742-747.
126. Zhong W, Li Q, Xie G et al. Dietary fat sources differentially modulate intestinal barrier and hepatic inflammation in alcohol-induced liver injury in rats. Am J Physiol Gastrointest Liver Physiol 2013; 305: G919-G932.
127. Nordestgaard BG, Hjelms E, Stender S, Kjeldsen K. Different efflux pathways for high and low density lipoproteins from porcine aortic intima. Arteriosclerosis 1990; 10: 477-485.
128. Levels JH, Abraham PR, van den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001; 69: 2821-2828.
129. de Haas CJ, van Leeuwen HJ, Verhoef J, van Kessel KP, van Strijp JA. Analysis of lipopolysaccharide (LPS)-binding characteristics of serum components using gel filtration of FITC-labeled LPS. J Immunol Methods 2000; 242: 79-89.
130. Wurfel MM, Wright SD. Lipopolysaccharide-binding protein and soluble CD14 transfer lipopolysaccharide to phospholipid bilayers: preferential interaction with particular classes of lipid. J Immunol 1997; 158: 3925-3934.
131. Gautier T, Lagrost L. Plasma PLTP (phospholipid-transfer protein): an emerging role in 'reverse lipopolysaccharide transport' and innate immunity. Biochem Soc Trans 2011; 39: 984-988.
132. Schulthess G, Compassi S, Werder M, Han CH, Phillips MC, Hauser H. Intestinal sterol absorption mediated by scavenger receptors is competitively inhibited by amphipathic peptides and proteins. Biochemistry 2000; 39: 12623-12631.
133. Williams DL, Temel RE, Connelly MA. Roles of scavenger receptor BI and APO A-I in selective uptake of HDL cholesterol by adrenal cells. Endocr Res 2000; 26: 639-651.
134. Urban S, Zieseniss S, Werder M, Hauser H, Budzinski R, Engelmann B. Scavenger receptor BI transfers major lipoprotein-associated phospholipids into the cells. J Biol Chem 2000; 275: 33409-33415.
135. Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, Von EA. High-density lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res 2009; 104: 1142-1150.
136. Cavelier C, Ohnsorg PM, Rohrer L, Von EA. The beta-chain of cell surface F(0)F(1) ATPase modulates apoA-I and HDL transcytosis through aortic endothelial cells. Arterioscler Thromb Vasc Biol 2012; 32: 131-139.
137. Rohrer L, Cavelier C, Fuchs S, Schluter MA, Volker W, Von EA. Binding, internalization and transport of apolipoprotein A-I by vascular endothelial cells. Biochim Biophys Acta 2006; 1761: 186-194.
138. Cavelier C, Rohrer L, Von EA. ATP-binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ Res 2006; 99: 1060-1066.
139. Martinez LO, Najib S, Perret B, Cabou C, Lichtenstein L. Ecto-F1-ATPase/P2Y pathways in metabolic and vascular functions of high density lipoproteins. Atherosclerosis 2015; 238: 89-100.
140. Parton RG, del Pozo MA. Caveolae as plasma membrane sensors, protectors and organizers. Nat Rev Mol Cell Biol 2013; 14: 98-112.
141. Babitt J, Trigatti B, Rigotti A et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272: 13242-13249.
142. Revelo XS, Luck H, Winer S, Winer DA. Morphological and inflammatory changes in visceral adipose tissue during obesity. Endocr Pathol 2014; 25: 93-101.
143. Eichbaum EB, Harris HW, Kane JP, Rapp JH. Chylomicrons can inhibit endotoxin activity in vitro. J Surg Res 1991; 51: 413-416.
144. Read TE, Grunfeld C, Kumwenda Z et al. Triglyceride-rich lipoproteins improve survival when given after endotoxin in rats. Surgery 1995; 117: 62-67.
145. Azhar S, Reaven E. Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis. Mol Cell Endocrinol 2002; 195: 1-26.
146. Kozarsky KF, Donahee MH, Rigotti A, Iqbal SN, Edelman ER, Krieger M. Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels. Nature 1997; 387: 414-417.
147. Schmitz G, Robenek H, Lohmann U, Assmann G. Interaction of high density lipoproteins with cholesteryl ester-laden macrophages: biochemical and morphological characterization of cell surface receptor binding, endocytosis and resecretion of high density lipoproteins by macrophages. EMBO J 1985; 4: 613-622.
148. Henning MF, Sanchez S, Bakas L. Visualization and analysis of lipopolysaccharide distribution in binary phospholipid bilayers. Biochem Biophys Res Commun 2009; 383: 22-26.
149. Murano I, Rutkowski JM, Wang QA, Cho YR, Scherer PE, Cinti S. Time course of histomorphological changes in adipose tissue upon acute lipoatrophy. Nutr Metab Cardiovasc Dis 2013; 23: 723-731.
150. Cai L, Wang Z, Ji A, Meyer JM, van der Westhuyzen DR. Scavenger receptor CD36 expression contributes to adipose tissue inflammation and cell death in diet-induced obesity. PLoS One 2012; 7: e36785.
151. Nguyen DV, Drover VA, Knopfel M, Dhanasekaran P, Hauser H, Phillips MC. Influence of class B scavenger receptors on cholesterol flux across the brush border membrane and intestinal absorption. J Lipid Res 2009; 50: 2235-2244.
152. Goudriaan JR, Dahlmans VE, Febbraio M et al. Intestinal lipid absorption is not affected in CD36 deficient mice. Mol Cell Biochem 2002; 239: 199-202.
153. Fischer-Posovszky P, Wang QA, Asterholm IW, Rutkowski JM, Scherer PE. Targeted deletion of adipocytes by apoptosis leads to adipose tissue recruitment of alternatively activated M2 macrophages. Endocrinology 2011; 152: 3074-3081.
154. Spalding KL, Arner E, Westermark PO et al. Dynamics of fat cell turnover in humans. Nature 2008; 453: 783-787.
155. Luche E, Cousin B, Garidou L et al. Metabolic endotoxemia directly increases the proliferation of adipocyte precursors at the onset of metabolic diseases through a CD14-dependent mechanism. Mol Metab 2013; 2: 281-291.
156. Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010; 140: 900-917.
157. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009; 2: re3.
158. Cai L, Wang ZF, Meyer JM FAU - Ji A, Ji AF, van der Westhuyzen DR. Macrophage SR-BI regulates LPS-induced pro-inflammatory signaling in mice and isolated macrophages.
159. Balmer ML, Slack E, De GA et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med 2014; 6: 237ra66.
160. Randolph GJ, Miller NE. Lymphatic transport of high-density lipoproteins and chylomicrons. J Clin Invest 2014; 124: 929-935.
161. Li Z, Perlik V, Feleder C, Tang Y, Blatteis CM. Kupffer cell-generated PGE2 triggers the febrile response of guinea pigs to intravenously injected LPS. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1262-R1270.
162. Malerod L, Juvet K, Gjoen T, Berg T. The expression of scavenger receptor class B, type I (SR-BI) and caveolin-1 in parenchymal and nonparenchymal liver cells. Cell Tissue Res 2002; 307: 173-180.
163. de Vries MA, Klop B, Janssen HW, Njo TL, Westerman EM, Castro CM. Postprandial inflammation: targeting glucose and lipids. Adv Exp Med Biol 2014; 824: 161-170.
164. Ilievski V, Cho Y, Katwala P et al. TLR4 expression by liver resident cells mediates the development of glucose intolerance and insulin resistance in experimental periodontitis. PLoS One 2015; 10: e0136502.
165. Harris HW, Grunfeld C, Feingold KR et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993; 91: 1028-1034.
166. Read TE, Harris HW, Grunfeld C et al. Chylomicrons enhance endotoxin excretion in bile. Infect Immun 1993; 61: 3496-3502.
167. Kumwenda ZL, Wong CB, Johnson JA, Gosnell JE, Welch WJ, Harris HW. Chylomicron-bound endotoxin selectively inhibits NF-kappaB activation in rat hepatocytes. Shock 2002; 18: 182-188.
168. Choi YJ, Im E, Chung HK, Pothoulakis C, Rhee SH. TRIF mediates Toll-like receptor 5-induced signaling in intestinal epithelial cells. J Biol Chem 2010; 285: 37570-37578.
169. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005; 17: 338-344.
170. Cario E. Barrier-protective function of intestinal epithelial Toll-like receptor 2. Mucosal Immunol 2008; 1(Suppl 1): S62-S66.
171. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 2007; 132: 1359-1374.
172. Caricilli AM, Picardi PK, de Abreu LL et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol 2011; 9: e1001212.
173. Eun CS, Kim YS, Han DS, Choi JH, Lee AR, Park YK. Lactobacillus casei prevents impaired barrier function in intestinal epithelial cells. APMIS 2011; 119: 49-56.
174. Larsson E, Tremaroli V, Lee YS et al. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut 2012; 61: 1124-1131.
175. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 1025-1035.